Remoxy’s "Complete Response" Letter Has No Clear Culprit But Many Suspects
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Legal and safety issues continue to swirl around Pfizer and Pain Therapeutics’ Remoxy as it deals with the product’s second “complete response” letter in less than three years.